iptacopan

iptacopan. It is a first-in-class, oral, small molecule inhibitor of factor B, a key component of the alternative complement pathway. Developed by the multinational pharmaceutical company Novartis, it is approved for the treatment of paroxysmal nocturnal hemoglobinuria in several regions, including the United States and the European Union. Its development represents a significant shift towards targeted, oral therapies for complement-mediated diseases.

Medical uses

It is indicated for the treatment of paroxysmal nocturnal hemoglobinuria in adults, a rare and life-threatening hematologic disease characterized by complement-mediated intravascular hemolysis. Clinical trials, such as the pivotal APPLY-PNH study, demonstrated its efficacy in increasing hemoglobin levels and reducing the need for blood transfusions compared to anti-C5 therapies like eculizumab or ravulizumab. Its approval by the Food and Drug Administration and the European Medicines Agency provides a new therapeutic option for patients with this chronic condition.

Mechanism of action

It acts as a potent and selective inhibitor of factor B, a serine protease essential for the activation and amplification of the alternative complement pathway. By binding to the active site of factor B, it prevents the formation of the C3 convertase complex, specifically C3bBb. This inhibition blocks the central amplification loop of the complement cascade, thereby reducing the downstream generation of C5a and the membrane attack complex, which are responsible for cell lysis and inflammation in PNH.

Adverse effects

Common adverse reactions reported in clinical trials include headache, nasopharyngitis, diarrhea, abdominal pain, and infections such as COVID-19. As it affects the innate immune system, there is a potential increased risk for encapsulated bacterial infections, notably from organisms like Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Vaccination against these pathogens is recommended prior to initiation of therapy, in accordance with guidelines from the Centers for Disease Control and Prevention.

Pharmacology

It exhibits high oral bioavailability and binds reversibly to human factor B with high affinity, demonstrating potent inhibition of the alternative pathway in human whole blood assays. The drug is primarily metabolized by CYP3A4 enzymes, and concomitant use with strong CYP3A4 inducers or inhibitors may require dose adjustments. Pharmacodynamic studies show that it achieves sustained suppression of alternative pathway activity, as measured by the AP Wieslab assay, supporting its twice-daily dosing regimen.

History and society

The compound was discovered and developed by scientists at Novartis Institutes for BioMedical Research. Its clinical development program was accelerated following positive results from early-phase studies presented at major congresses like the American Society of Hematology annual meeting. The approval of the drug, marketed as Fabhalta, was supported by patient advocacy groups such as the Aplastic Anemia and MDS International Foundation, highlighting the collaborative effort to address unmet needs in rare diseases.

Research

Ongoing clinical investigations are evaluating its efficacy in other complement-mediated disorders, including C3 glomerulopathy, immune complex membranoproliferative glomerulonephritis, and atypical hemolytic uremic syndrome. Research is also exploring its potential in geographic atrophy secondary to age-related macular degeneration. These studies, conducted globally at institutions like the National Institutes of Health, aim to expand the therapeutic landscape for diseases driven by dysregulation of the complement system. Category:Drugs Category:Complement system